Truist Lowers DexCom (DXCM) PT to $94 Ahead of Q3 MedTech Sector Preview, Maintains Buy Rating
DexCom Inc. (NASDAQ:DXCM) is a top growth stock on NASDAQ. Analysts anticipate strong Q3 results in the MedTech sector, driven by continuous glucose monitors and insulin pumps.